摘要
为观察靶向治疗V-raf鼠肉瘤病毒癌基因同源体B(BRAF)V600E突变型晚期结直肠癌患者的疗效,将56例BRAFV600E突变型晚期结直肠癌患者随机分为对照组和观察组,每组28例。对照组患者采用BRAF抑制剂治疗,观察组患者采用BRAF抑制剂和西妥昔单抗治疗,观察2组患者的疗效、血清肿瘤标志物水平以及不良反应发生率。结果显示,观察组患者总有效率明显高于对照组(P<0.05);治疗前2组患者血清肿瘤标志物水平比较差异无统计学意义(P>0.05),治疗后观察组患者血清肿瘤标志物水平低于对照组(P<0.05);2组患者均无明显不良反应(P>0.05)。结果表明,对BRAFV600E突变型晚期结直肠癌患者行靶向治疗时,选择BRAF抑制剂和西妥昔单抗治疗,疗效显著,且安全性高。
This study was to observe the effect of targeting therapy for BRAFV600Emutant late colorectal cancer,randomly divided 56patients with BRAFV600Emutant late colorectal cancer into control group(28 cases,treated with BRAF inhibitor)and observation group(28cases,with BRAF inhibitor plus mono-antibody mab);then,observed both groups'effect,serum tumor-mark's level,and unward reaction incidence.As results,in total effective rate observation group was significantly higher than control group(P<0.05);before treatment,both groups'serum tumor-mraks'level had no statistical difference each after(P>0.05),but after treatment observation groups'levels was lower than control groups'one(P<0.05),in both groups no significant unward reactions were found(P>0.05).Results show that enrolling BRAF inhibitor and mab.mono-antibody in targeting therapy for BRAFV600Emutant late colorectal cancer has significant effect and high safety.
作者
王环环
WANG Huan-huan(Dept.of Oncology,Juye County's People's Hospital,Heze,Shandong 274900)
出处
《中国肛肠病杂志》
2021年第10期10-12,共3页
Chinese Journal of Coloproctology
